Inflammatory vaginitis in women on long-term rituximab treatment for autoimmune disorders.
Background: Consequences of long-term B cell depletion with rituximab are not well understood. We describe inflammatory vaginitis as a potential side effect of long-term rituximab treatment, distinct from previously described vulvovaginal pyoderma gangrenosum.Methods: We performed a retrospective an...
| Publicado en: | BMC Women's Health Vol. 21; no. 1; pp. 1 - 8 |
|---|---|
| Autores principales: | , , , , , , , , |
| Formato: | research Journal Article |
| Publicado: |
BioMed Central
8/5/2021
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=151774407&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 151774407 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 14726874 1CIP jtl: BMC Women's Health issn: 14726874 maglogo: N pubinfo: dt: 8/5/2021 vid: 21 iid: 1 pid: 24147 pub: BioMed Central artinfo: ui: 151774407 151774407 NLM34353326 151774407 10.1186/s12905-021-01423-0 NLM34353326 151774407 ppf: 1 ppct: 7 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Inflammatory vaginitis in women on long-term rituximab treatment for autoimmune disorders. aug: au: Yockey, Laura Dowst, Sarah Zonozi, Reza Huizenga, Noah Murphy, Patrick Laliberte, Karen Rosenthal, Jillian Niles, John L. Mitchell, Caroline M. affil: Department of Medicine, Massachusetts General Hospital, Boston, MA, USA sug: subj: Autoimmune Diseases Vaginitis Drug Therapy Vaginal Discharge Vaginitis Epidemiology Aged Young Adult Human Adult Female Retrospective Design Middle Age Comparative Studies Multicenter Studies Evaluation Research Validation Studies Scales Aged: 65+ years Adult: 19-44 years Middle Aged: 45-64 years Female ab: Background: Consequences of long-term B cell depletion with rituximab are not well understood. We describe inflammatory vaginitis as a potential side effect of long-term rituximab treatment, distinct from previously described vulvovaginal pyoderma gangrenosum.Methods: We performed a retrospective analysis of women treated with rituximab for more than 1 year to determine the prevalence and clinical characteristics of vaginitis cases. We conducted a case-control analysis with up to 3 controls for each vaginitis case.Results: We identified sixteen inflammatory vaginitis cases. Women with vaginitis were age 23-68 (median 42), primarily being treated for ANCA-associated vasculitis (11/16; 69%). Most reported copious vaginal discharge (100%) and pain with sex (75%). All women with return of circulating B-cells to > 10 cells/mL had complete (5/9) or significant (4/9) improvement in symptoms. In case-control analysis there was no significant difference in length of B-cell depletion, immune parameters, creatinine levels, and history of neutropenia.Conclusion: Inflammatory vaginitis is a potential side effect of prolonged continuous B cell depletion with rituximab. More studies are needed to characterize the incidence and etiology of vaginitis among women on long term rituximab therapy and establish a causal relationship. pubtype: Academic Journal doctype: research Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|